Get the Stockscreener App
8.40
1.29%
-0.11
After Hours:
8.56
0.16
+1.90%
Immunome Inc stock is traded at $8.40, with a volume of 984.49K.
It is down -1.29% in the last 24 hours and down -8.70% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$8.51
Open:
$8.56
24h Volume:
984.49K
Relative Volume:
0.94
Market Cap:
$730.90M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.5365
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-1.75%
1M Performance:
-8.70%
6M Performance:
-16.91%
1Y Performance:
-40.68%
1-Day Range:
$7.96
$8.6851
1-Week Range:
$7.96
$9.27
52-Week Range:
$5.1501
$16.81
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
8.40 | 743.96M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.96 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.12 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.96 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.70 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
How Immunome Inc. stock performs during market volatilityFree Exclusive Investment Tips - Newser
What makes Immunome Inc. stock price move sharply2x 3x 5x Pick Alert - Newser
Why Immunome Inc. stock attracts strong analyst attentionFree Investment Community - Newser
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Wealth Enhancement Advisory Services LLC Boosts Stock Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? - MSN
Immunome's Inducement Grants: A Balancing Act Between Talent Acquisition and Equity Dilution - AInvest
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Trend Tracker for (IMNM) - news.stocktradersdaily.com
Immunome, Inc. (NASDAQ:IMNM) Stake Raised by Wealth Enhancement Advisory Services LLC - Defense World
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - sharewise
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 14,328 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Bank of America Corp DE Sells 44,020 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Elects New Directors at Annual Meeting - TipRanks
Squarepoint Ops LLC Reduces Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Jane Street Group LLC - Defense World
Lifesci Capital Has Bullish Outlook for Immunome Q2 Earnings - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 - BioSpace
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
Immunome Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Two Sigma Advisers LP Makes New $512,000 Investment in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Nuveen Asset Management LLC - Defense World
Insider Buying: Jean Bienaime Acquires Additional Shares of Immu - GuruFocus
14,477 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by ProShare Advisors LLC - Defense World
Two Sigma Investments LP Purchases Shares of 154,467 Immunome, Inc. (NASDAQ:IMNM) - Defense World
Millennium Management LLC Buys New Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
BNP Paribas Financial Markets Invests $70,000 in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Deutsche Bank AG Has $489,000 Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - MSN
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(IMNM) Trading Report - news.stocktradersdaily.com
Immunome to Present at Upcoming Investor Conferences - BioSpace
Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences - Stock Titan
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Northern Trust Corp - Defense World
Immunome, Inc. Reports Q1 2025 Financial Results - TipRanks
Immunome stock rating cut to Hold by Boral Capital - Investing.com Nigeria
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Leerink Partnrs Has Strong Estimate for Immunome Q2 Earnings - Defense World
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):